Daratumumab Retreatment in Participants With Multiple Myeloma Who Have Been Previously Treated With Daratumumab
Status:
Recruiting
Trial end date:
2026-02-15
Target enrollment:
Participant gender:
Summary
The purpose of this study is to compare the efficacy (rate of very good partial response
[VGPR] or better as best response as defined by the International Myeloma Working Group
[IMWG] criteria) of daratumumab subcutaneous (Dara-SC) in combination with carfilzomib and
dexamethasone (Kd) with the efficacy of Kd in participants with relapsed refractory multiple
myeloma who were previously exposed to daratumumab to evaluate daratumumab retreatment.